Gilead Sciences' COVID-19 Treatment Earns Conditional Approval in Europe
Hospitalized coronavirus patients in the EU should find it a lot easier to access Veklury, the drug from Gilead Sciences (NASDAQ: GILD) formerly known as remdesivir. The European Commission granted conditional approval to the broad-spectrum antiviral treatment on Friday.
Now, Gilead can market Veklury throughout the EU for the treatment of COVID-19 in patients 12 years of age and older with pneumonia serious enough to require supplemental oxygen in a hospital setting.
Image source: Getty Images.
Source Fool.com
